Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627 · cited 1×
“Second, angiogenesis (the growth of new capillaries from pre-existing blood vessels) is characteristic of most aggressive solid tumor”
Characteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793 · cited 1×
“Stable cell lines expressing the fusion proteins were generated in HEK 293 cell”
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890 · cited 1×
“IFN-γ both upregulates antigen presentation on class I and class II major histocompatibility complexes and potentiates the activity of phagocytic cells, NK cells, and T-cell”
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197
A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification
Hopp, T. P., Prickett, K. S., Price, V. L., Libby, R. T., March, C. J., Pat Cerretti, D., Urdal, D. L., & Conlon, P. J. (1988) · Bio/Technology · doi:10.1038/nbt1088-1204 · Cited by 957
Recombinant IL-12 administration induces tumor regression in association with IFN- gamma production.
Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., et al. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.4.1697 · Cited by 780
Inhibition of Angiogenesis In Vivo by Interleukin 12
Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., & Folkman, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.8.581 · Cited by 722
Jain, R. K., & Baxter, L. T. (1988) · PubMed · Cited by 714
Atkins, M. B., Robertson, M. J., Gordon, M. S., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D. J., Garzone, P. D., et al. (1997) · PubMed · Cited by 672
Alkaline Phosphatase Activity in Mouse Teratoma
Bernstine, E. G., Hooper, M. L., Grandchamp, S., & Ephrussi, B. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.12.3899 · Cited by 617
Corbett, T. H., Griswold, D. P., Roberts, B. J., Peckham, J. C., & Schabel, F. M. (1975) · PubMed · Cited by 584
Zardi, L., Carnemolla, B., Siri, A., Petersen, T. E., Paolella, G., Sebastio, G., & Baralle, F. E. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02509.x · Cited by 338
Self-citationCarnemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M. R., Bigotti, A., & Natali, P. G. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.3.1139 · Cited by 335
Self-citationThe fibronectin isoform containing the ed‐b oncofetal domain: A marker of angiogenesis
Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kaczmarek, J., Querze, G., & Zardi, L. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590507 · Cited by 316
Self-citationViti, F., Tarli, L., Giovannoni, L., Zardi, L., & Neri, D. (1999) · PubMed · Cited by 235
Self-citationNilsson, F., Kosmehl, H., Zardi, L., & Neri, D. (2001) · PubMed · Cited by 235
Self-citationElucidation of the mechanism enabling tumor selective prodrug monotherapy.
Bosslet, K., Straub, R. H., Blumrich, M., Czech, J., Gerken, M., Sperker, B., Kroemer, H. K., Gesson, J., Koch, M. C., & Monneret, C. (1998) · PubMed · Cited by 225
The Toxicology of Interleukin-12: A Review
Car, B. D., Eng, V. M., Lipman, J. M., & Anderson, T. D. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700112 · Cited by 220
A High-Affinity Human Antibody That Targets Tumoral Blood Vessels
Tarli, L., Balza, E., Viti, F., Borsi, L., Castellani, P., Berndorff, D., Dinkelborg, L., Neri, D., & Zardi, L. (1999) · Blood · doi:10.1182/blood.v94.1.192.413k22_192_198 · Cited by 206
Self-citationIL-12 induces T helper 1-directed antitumor response
Tsung, K., Meko, J. B., Peplinski, G. R., Tsung, Y. L., & Norton, J. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.7.3359 · Cited by 184
Kaczmarek, J., Castellani, P., Nicolo, G., Spina, B., Allemanni, G., & Zardi, L. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590104 · Cited by 159
Self-citationBioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo
Lieschke, G. J., Rao, P. K., Gately, M. K., & Mulligan, R. C. (1997) · Nature Biotechnology · doi:10.1038/nbt0197-35 · Cited by 154
Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
King, D., Turner, A. V., Farnsworth, A., Adair, J. R., Owens, R. J., Pedley, R. B., Baldock, D., Proudfoot, K. A., Lawson, A. D. G., & Beeley, N. (1994) · PubMed · Cited by 139
Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.
Duda, D. G., Sunamura, M., Lozonschi, L., Kodama, T., Egawa, S., Matsumoto, G., Shimamura, H., Shibuya, K., Takeda, K., & Matsuno, S. (2000) · PubMed · Cited by 127
Birchler, M. T., Viti, F., Zardi, L., Spiess, B. M., & Neri, D. (1999) · Nature Biotechnology · doi:10.1038/13679 · Cited by 119
Self-citationDemartis, S., Tarli, L., Borsi, L., Zardi, L., & Neri, D. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100480 · Cited by 90
Self-citationImmune-inflammatory mechanisms in IFNγ-mediated anti-tumor activity
Tannenbaum, C. S., & Hamilton, T. A. (2000) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0314 · Cited by 85
Interleukin-12 as an Adjuvant for Cancer Immunotherapy
Rodolfo, M., & Colombo, M. P. (1999) · Methods · doi:10.1006/meth.1999.0836 · Cited by 72
Measurement of Human and Mouse Interleukin‐12
Gately, M. K., Chizzonite, R., & Presky, D. H. (1995) · Current Protocols in Immunology · doi:10.1002/0471142735.im0616s15 · Cited by 70
VL-VH expression by monoclonal antibodies recognizing avian lysozyme.
Smith‐Gill, S. J., Mainhart, C. R., Lavoie, T., Rudikoff, S., & Potter, M. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.2.963 · Cited by 61
Antibody-Based Targeting of Angiogenesis
Halin, C., & Neri, D. (2001) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v18.i3.20 · Cited by 32
Self-citation
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Self-citationVascular Targeting Agents as Cancer Therapeutics
Thorpe, P. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0642-03 · Cited by 577
New insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
Metadata
- Authors
- Halin, C., Rondini, S., Nilsson, F., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D.
- Venue
- Nature Biotechnology
- Published
- 2002-03
- Volume
- 20
- Issue
- 3
- Pages
- 264-269
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2074348188
- Cited by
- 252
- References
- 33
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.